Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2000 1
2001 3
2003 4
2004 3
2005 1
2006 1
2008 2
2009 3
2010 3
2011 1
2013 2
2014 3
2015 4
2016 7
2017 4
2018 11
2019 1
2020 6
2021 3
2022 4
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for axel tolerance
Search for Axel Tollance instead (3 results)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. Coskun T, et al. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. Mol Metab. 2018. PMID: 30473097 Free PMC article. Clinical Trial.
Doses higher than 5 mg were attained by titration, dulaglutide (DU) was used as a positive control. The primary objective was to investigate safety and tolerability of LY3298176. RESULTS: LY3298176 activated both GIP and GLP-1 receptor signaling in vitro and showed glucose …
Doses higher than 5 mg were attained by titration, dulaglutide (DU) was used as a positive control. The primary objective was to investigate …
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.
De Greef A, Ghislain PD, de Montjoye L, Baeck M. De Greef A, et al. Adv Ther. 2023 May;40(5):2509-2514. doi: 10.1007/s12325-023-02490-5. Epub 2023 Mar 21. Adv Ther. 2023. PMID: 36944819 Free PMC article.
INTRODUCTION: The efficacy and safety of upadacitinib in atopic dermatitis have been defined in clinical trials, but long-term real-life experience, essential for clinical decision-making, is still limited. We aimed to assess the effectiveness and tolerance of upadacitinib …
INTRODUCTION: The efficacy and safety of upadacitinib in atopic dermatitis have been defined in clinical trials, but long-term real-life exp …
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Frias JP, et al. Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293770 Clinical Trial.
The primary efficacy outcome was change in HbA(1c) from baseline to 26 weeks in the modified intention-to-treat (mITT) population (all patients who received at least one dose of study drug and had at least one postbaseline measurement of any outcome). ...INTERPRETATION: Th …
The primary efficacy outcome was change in HbA(1c) from baseline to 26 weeks in the modified intention-to-treat (mITT) population (all patie …
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.
Taylor PC, Laedermann C, Alten R, Feist E, Choy E, Haladyj E, De La Torre I, Richette P, Finckh A, Tanaka Y. Taylor PC, et al. J Clin Med. 2023 Jul 6;12(13):4527. doi: 10.3390/jcm12134527. J Clin Med. 2023. PMID: 37445562 Free PMC article. Review.
In several pivotal Phase II and III RA trials (RA-BALANCE, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BEYOND), up to seven years of baricitinib treatment was well tolerated and provided rapid and sustained efficacy, which was confirmed in real-world settings. ...
In several pivotal Phase II and III RA trials (RA-BALANCE, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BEYOND), up to seven years of bariciti …
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Ison MG, et al. Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093/cid/ciae010. Online ahead of print. Clin Infect Dis. 2024. PMID: 38253338
CONCLUSION: One RSVPreF3 OA dose was efficacious against RSV-LRTD over 2 RSV seasons in 60-year-olds. Revaccination 1 year post-dose 1 was well tolerated but did not seem to provide additional efficacy benefit in the overall study population. ...
CONCLUSION: One RSVPreF3 OA dose was efficacious against RSV-LRTD over 2 RSV seasons in 60-year-olds. Revaccination 1 year post-dose 1 was w …
Patient Blood Management in Liver Transplant-A Concise Review.
Pérez-Calatayud AA, Hofmann A, Pérez-Ferrer A, Escorza-Molina C, Torres-Pérez B, Zaccarias-Ezzat JR, Sanchez-Cedillo A, Manuel Paez-Zayas V, Carrillo-Esper R, Görlinger K. Pérez-Calatayud AA, et al. Biomedicines. 2023 Apr 4;11(4):1093. doi: 10.3390/biomedicines11041093. Biomedicines. 2023. PMID: 37189710 Free PMC article. Review.
This approach is based on three pillars of treatment: (1) detecting and correcting anemia and thrombocytopenia, (2) minimizing iatrogenic blood loss, detecting, and correcting coagulopathy, and (3) harnessing and increasing anemia tolerance. This review emphasizes the impo …
This approach is based on three pillars of treatment: (1) detecting and correcting anemia and thrombocytopenia, (2) minimizing iatrogenic bl …
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J, Chien J, Zhang Q, Chigutsa E, Landschulz W, Syring K, Wullenweber P, Haupt A, Kazda C. Frias J, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):158-168. doi: 10.1016/S2213-8587(22)00388-6. Epub 2023 Feb 6. Lancet Diabetes Endocrinol. 2023. PMID: 36758572 Clinical Trial.
The hypoglycaemia (3.9 mmol/L or 70 mg/dL) event rates (hypoglycaemia events per patient per year) in the BIF groups were 25% lower than those in the degludec group (treatment ratio BIF-A1 vs degludec was 0.75 [0.61-0.93]; and BIF-A2 vs degludec was 0.74 [0.58-0.94]). BIF was wel …
The hypoglycaemia (3.9 mmol/L or 70 mg/dL) event rates (hypoglycaemia events per patient per year) in the BIF groups were 25% lower than tho …
Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
De Greef A, Thirion R, Ghislain PD, Baeck M. De Greef A, et al. Dermatol Ther (Heidelb). 2023 Nov;13(11):2869-2877. doi: 10.1007/s13555-023-01030-x. Epub 2023 Sep 17. Dermatol Ther (Heidelb). 2023. PMID: 37717224 Free PMC article.
METHODS: We retrospectively evaluated the effectiveness and tolerance of baricitinib in alopecia areata in a real-life Belgian monocentric adult cohort. ...
METHODS: We retrospectively evaluated the effectiveness and tolerance of baricitinib in alopecia areata in a real-life Belgian monoce …
Two regulatory T cell populations in the visceral adipose tissue shape systemic metabolism.
Torres SV, Man K, Elmzzahi T, Malko D, Chisanga D, Liao Y, Prout M, Abbott CA, Tang A, Wu J, Becker M, Mason T, Haynes V, Tsui C, Shakiba MH, Hamada D, Britt K, Groom JR, McColl SR, Shi W, Watt MJ, Le Gros G, Pal B, Beyer M, Vasanthakumar A, Kallies A. Torres SV, et al. Nat Immunol. 2024 Mar;25(3):496-511. doi: 10.1038/s41590-024-01753-9. Epub 2024 Feb 14. Nat Immunol. 2024. PMID: 38356058
Regulatory T (T(reg)) cells restrain inflammation to preserve VAT homeostasis and glucose tolerance. Here, we show that the VAT harbors two distinct T(reg) cell populations: prototypical serum stimulation 2-positive (ST2(+)) T(reg) cells that are enriched in males and a pr …
Regulatory T (T(reg)) cells restrain inflammation to preserve VAT homeostasis and glucose tolerance. Here, we show that the VAT harbo …
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
Yalkinoglu Ö, Becker A, Krebs-Brown A, Vetter C, Lüpfert C, Perrin D, Heuer J, Biedert H, Hirt S, Bytyqi A, Bachmann A, Strotmann R. Yalkinoglu Ö, et al. Invest New Drugs. 2023 Aug;41(4):596-605. doi: 10.1007/s10637-023-01378-z. Epub 2023 Jul 6. Invest New Drugs. 2023. PMID: 37415001 Free PMC article.
Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer harboring MET exon 14 skipping alterations. The aims of this work were to investigate the potential for drug-drug …
Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small c …
74 results